Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

FATE $5.27 1.5700 +42.43%
ADXS $5.61 0.7500 +15.43%
ZIOP $4.80 0.5300 +12.41%
CVM $0.65 0.0657 +11.24%
ISIS $65.09 5.5400 +9.30%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

IMGN $6.11 -4.7400 -43.69%
CBMG $12.55 -1.1400 -8.33%
GTXI $0.89 -0.0800 -8.25%
PARD $0.16 -0.0100 -5.88%
GLYC $8.64 -0.4200 -4.64%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | Next > | Last >>

The American Society of Hematology Announces 2015 Scholar Award Recipients

(ASH) Dec 2, 2014 - The American Society of Hematology (ASH) today announced the recipients of its 2015 Scholar Awards.
read press release 

American Society of Hematology Honors Senator Barbara Mikulski and Patient Advocate Kathy Giusti

(ASH) Dec 2, 2014 - The American Society of Hematology (ASH) will recognize Senator Barbara Mikulski (D-MD) and Kathy Giusti, founder of the Multiple Myeloma Research Foundation, with awards for their outstanding support and advocacy for biomedical research and the practice of hematology at the 56th ASH Annual Meeting in San Francisco.
read press release 

Hematology Advances Take Center Stage at ASH

(MedPage Today) Dec 5, 2014 - The rapid pace and broad scope of clinical development in hematology will meld in a single venue during the 56th American Society of Hematology (ASH) Annual Meeting, which begins here today.
read article (free registration required) 

The Evolving Relationship Between Health Plans and Providers

(Albany Times-Union blog) Dec 6, 2014 - This past week there was mention publicly of a large health care provider for oncology services sending notice of their termination with a large health care plan in the Capital Region.
read article 

Viewing a Genome on a Blackberry Phone

(Forbes) Dec 6, 2014 - Patrick Soon-Shiong, the richest doctor in the world, and Blackberry Chief Executive John Chen made some news at Thursday's Forbes Healthcare Summit, revealing a new app that will allow doctors to review a cancer patient's genes on a Blackberry phone.
read article 

Takeda Announces Formalization of Takeda Oncology to Enhance Discovery, Development and Global Commercialization of Breakthrough Cancer Medicines

(Yahoo! Finance) Dec 6, 2014 - Takeda Pharmaceutical Company Limited today announced its global oncology business unit, headquartered in Cambridge, MA, will be called Takeda Oncology.
read article 

Attacking Multiple Myeloma on Multiple Fronts

(Celgene) Dec 5, 2014 - In recent years, scientists have determined that tumors are a mixture of genetic mutations. A 2012 study in the New England Journal of Medicine, for example, revealed wide genetic variation within a single mass of kidney cancer cells. Now, a recent Cancer Cell study unveils similar genetic complexities in multiple myeloma. Physicians believe the findings can have immediate implications for treatment strategies.
read article 

Circulating RNA May Provide Prognostic Tool For Multiple Myeloma

(Dana-Farber) Dec 6, 2014 - The "molecular mail" sent by multiple myeloma cells provides clues to how well patients with the disease are likely to respond to treatment, according to a study being presented at the annual meeting of the American Society of Hematology (ASH) by researchers at Dana-Farber Cancer Institute.
read press release 

Interim Data From Phase 1 Dose Escalation Clinical Trial of TGR-1202 Demonstrates Significant Clinical Activity and Lack of Hepatic Toxicity in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma

(TheStreet) Dec 6, 2014 - TG Therapeutics, Inc. today announced updated clinical results from its ongoing Phase I single agent dose escalation study of TGR-1202, the Company's oral, once-daily, PI3K delta inhibitor.
read article 

MorphoSys and Xencor Publish Final Results From Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting

(CNBC) Dec 7, 2014 - MorphoSys AG and Xencor Inc. today announced the publication of final results of a Phase 1/2a trial evaluating MOR208 (formerly XmAb5574®) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).
read article 

Onconova Announces Data Presentation From Combination of Rigosertib and Azacitidine in MDS and Non-proliferative AML at the 2014 ASH Annual Meeting

(The Street) Dec 7, 2014 - Onconova Therapeutics, Inc. today announced the presentation of data from clinical trials of rigosertib in myelodysplastic syndromes (MDS) and non-proliferative acute myeloid leukemia (AML) at the 56th American Society of Hematology (ASH) Annual Meeting in San Francisco, California, December 6-9, 2014.
read article 

ImmunoGen, Inc. Announces Encouraging IMGN529 Clinical Data Presented at 56th ASH Annual Meeting and Exposition

(CNBC) Dec 6, 2014 - ImmunoGen, Inc. today announced the presentation of encouraging clinical findings with its IMGN529 experimental therapy for B-cell malignancies at the American Society of Hematology (ASH) annual meeting (abstract #1760). These include objective responses at doses that were generally well tolerated.
read article 

Seattle Genetics Presents Data From SGN-CD19A Antibody-Drug Conjugate at ASH Annual Meeting

(MarketWatch) Dec 6, 2014 - Seattle Genetics, Inc. today presented data from two ongoing phase 1 clinical trials evaluating SGN-CD19A, an antibody-drug conjugate (ADC) in development for the treatment of B-cell malignancies, including non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL), at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Francisco, CA December 6-9, 2014.
read article 

Bortezomib (Velcade(R)) Plus Dexamethasone ("TBorD") in Patients With Relapsed/Refractory Multiple Myeloma Presented at ASH Annual Meeting

(Threshold) Dec 6, 2014 - Threshold Pharmaceuticals, Inc. today announced new preliminary data from the Phase 2 component of an ongoing Company-sponsored Phase 1/2 trial of TH-302, the Company's lead investigational anticancer drug, in combination with the proteasome inhibitor bortezomib (Velcade®) and low-dose dexamethasone ("TBorD") for the treatment of patients with relapsed/refractory multiple myeloma (MM).
read corporate press release 

Takeda Presents Phase 2 Data on Maintenance With Single-Agent Investigational Ixazomib in Patients With Newly Diagnosed Multiple Myeloma

(iStockAnalyst) Dec 7, 2014 - Takeda Pharmaceutical Company Limited today announced results from an open-label, Phase 2 study evaluating the safety and efficacy of oral, single-agent ixazomib (MLN9708) as maintenance therapy in patients with multiple myeloma (MM) who had received ixazomib, lenalidomide and dexamethasone as induction therapy.
read article 

Pharmacyclics/J&J's Imbruvica Shows Promise in MM

(PharmaTimes [UK]) Dec 7, 2014 - Pharmacyclics and Johnson & Johnson’s leukaemia and lymphoma drug Imbruvica has shown potential both as a single agent and as combination therapy in heavily pre-treated patients with multiple myeloma.
read article 

Seattle Genetics and Takeda Announce Four-Year Survival Data From ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting

(StreetInsider) Dec 7, 2014 - Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited today announced four-year overall survival (OS) data from the ADCETRIS (brentuximab vedotin) pivotal Phase 2 clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL).
read article 

Studies Compare Blood Clot Treatments, Illuminate Recurrence Risk in High-Risk Groups

(ASH) Dec 7, 2014 - Studies presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition compare new and standard-of-care treatments for blood clots and further illuminate clot risks in vulnerable populations, such as cancer patients.
read press release 

Study Shows Improved Survival in Aggressive Acute Myeloid Leukemia

(MD Anderson) Dec 7, 2014 - Patients who relapse in their battle with acute myeloid leukemia (AML) may benefit from a phase three study of therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin.
read press release 

Leukemia Therapy Shows Promise

(Wall Street Journal) Dec 7, 2014 - Researchers report that blocking a mutation with a drug developed by Agios and Celgene leads to complete or partial remissions in 56% of patients with advanced acute myeloid leukemia and other similar blood cancers in a small, continuing early study.
read article (paid subscription required) 

Novel Combinations of New and Existing Therapies Yield Promising Results For Leukemia Patients With Poor Prognoses

(ASH) Dec 7, 2014 – Recognizing that leukemia cannot be conquered with a “one-size-fits-all” approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for patient populations with historically poor prognoses, according to data presented today during the 56th American Society of Hematology (ASH) Annual Meeting and Exposition.
read press release 

Acceleron Drugs Reduce Anemia Caused by Rare Blood Disorders

(TheStreet) Dec 7, 2014 - Celgene has worldwide clinical development and marketing rights to the two Acceleron drugs, known as luspatercept and sotatercept.
read article 

New Strategies Boost Healthy Red Blood Cell Production to Target Anemia Across a Range of Blood Disorders

(ASH) Dec 7, 2014 - Emerging treatment approaches may reduce the burden of anemia associated with blood disorders by enhancing production of healthy red blood cells, according to data presented today at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition.
read press release 

Advances in Lymphoma and Multiple Myeloma Treatment Seek to Improve Outcomes For Patients With Hard-to-Treat Disease

(ASH) Dec 6, 2014 - New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition.
read press release 

Benefits Persist in T Cell Therapy For Children With Relapsed Leukemia

(CHOP) Dec 6, 2014 - An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia (ALL) continues to show highly promising results in children treated in a pilot study.
read press release